Foghorn Therapeutics (FHTX) Stock Price, News & Analysis

Company Overview

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Key Stats

• Today's Range: $4.91 to $5.34
• 50-Day Range: $4.91 to $9.35
• 52-Week Range: $2.70 to $10.25
• Volume: 142,422 shs
• Average Volume: 142,217 shs
• Market Capitalization: $274.07 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $13.80
• Consensus Rating: Moderate Buy

Foghorn Therapeutics Stock Analysis - MarketRank™

Foghorn Therapeutics scored higher than 58% of companies evaluated by MarketBeat, and ranked 448th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Foghorn Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Foghorn Therapeutics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Foghorn Therapeutics are expected to grow in the coming year, from ($1.58) to ($1.26) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Foghorn Therapeutics is -2.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Foghorn Therapeutics is -2.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.18% of the float of Foghorn Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Foghorn Therapeutics has a short interest ratio ("days to cover") of 5.7.

Change versus previous month

Short interest in Foghorn Therapeutics has recently decreased by 9.71%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Foghorn Therapeutics does not currently pay a dividend.

Dividend Growth

Foghorn Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.18% of the float of Foghorn Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Foghorn Therapeutics has a short interest ratio ("days to cover") of 5.7.

Change versus previous month

Short interest in Foghorn Therapeutics has recently decreased by 9.71%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.7 / 5
• News Sentiment: 0.14

News Sentiment

Foghorn Therapeutics has a news sentiment score of 0.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 16 news articles for Foghorn Therapeutics this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for FHTX on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Foghorn Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,716.00 in company stock.

Percentage Held by Insiders

Only 9.07% of the stock of Foghorn Therapeutics is held by insiders.

Percentage Held by Institutions

61.55% of the stock of Foghorn Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

FHTX Stock Analysis - Frequently Asked Questions

How have FHTX shares performed this year?

Foghorn Therapeutics' stock was trading at $6.45 on January 1st, 2024. Since then, FHTX stock has decreased by 23.6% and is now trading at $4.93.
View the best growth stocks for 2024 here.

How were Foghorn Therapeutics' earnings last quarter?

Foghorn Therapeutics Inc. (NASDAQ:FHTX) issued its quarterly earnings results on Thursday, August, 8th. The company reported ($0.45) earnings per share for the quarter, topping analysts' consensus estimates of ($0.60) by $0.15. The company earned $6.89 million during the quarter, compared to analysts' expectations of $6.60 million.

When did Foghorn Therapeutics IPO?

Foghorn Therapeutics (FHTX) raised $120 million in an IPO on Friday, October 23rd 2020. The company issued 7,500,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs, Morgan Stanley and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Who are Foghorn Therapeutics' major shareholders?

Top institutional shareholders of Foghorn Therapeutics include FMR LLC (11.39%), Raymond James & Associates (5.39%), Geode Capital Management LLC (1.22%) and State Street Corp (0.91%). Insiders that own company stock include Carlos Costa and Samuel Agresta.
View institutional ownership trends.

How do I buy shares of Foghorn Therapeutics?

Shares of FHTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Foghorn Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Foghorn Therapeutics investors own include Tesla (TSLA), JPMorgan Chase & Co. (JPM), Advanced Micro Devices (AMD), NVIDIA (NVDA), Netflix (NFLX), Meta Platforms (META) and Alphabet (GOOG).

Company Calendar

• Last Earnings: 8/08/2024
• Today: 12/23/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:FHTX
• CUSIP: N/A
• CIK: 1822462
• Web: foghorntx.com
• Phone: 617-586-3100
• Fax: N/A
• Employees: 120
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $13.80
• High Stock Price Target: $20.00
• Low Stock Price Target: $9.00
• Potential Upside/Downside: +168.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 5 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.92)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-98,430,000.00
• Net Margins: -357.53%
• Pretax Margin: -349.74%
• Return on Equity: N/A
• Return on Assets: -30.98%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.77
• Quick Ratio: 4.77

Sales & Book Value

• Annual Sales: $25.52 million
• Price / Sales: 11.20
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.83) per share
• Price / Book: -2.81

Miscellaneous

• Outstanding Shares: 55,593,000
• Free Float: 50,551,000
• Market Cap: $285.75 million
• Optionable: Optionable
• Beta: 3.10